The US FDA has approved once-daily Onyda XR as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

Around 1.7 million people in the UK consume energy drinks two or three times a week, and a third of children in the UK ...

Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for ...

The crystal structure of a second G protein–coupled receptor sheds light on these key pharmaceutical targets. In contrast, β2AR and essentially all of the other GPCRs are present at very low ...

In a study published in Cell Host & Microbe, a research team has demonstrated the causal link between microbial factors and ...

Overview A condition where the eye’s optic nerve, which provides information to the brain, is damaged with or without raised ...

Beta-blockers are effective at decreasing the morbidity and mortality associated with CHF. They lower the risk of all-cause mortality, cardiovascular mortality, sudden death, and death from ...

They administered the xylazine-based conjugates to mice and monitored how the mice moved and breathed when they were later ...

adrenergic receptor blocking agent that slows the sinus rate and decreases AV nodal conduction. The β-blocking activity of metoprolol has been shown by reduction in heart rate and cardiac output ...

Ergotamine tartrate 1mg, caffeine 100mg; tabs. Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and ...

However, it has been found that additional α-adrenergic blockade with carvedilol may increase the number of patients with hemodynamic responses resulting in a reduction in hepatic venous pressure ...

Ocuphire anticipates initiating the ZETA-2 Phase 2/3 trial of APX3330 for NPDR in early 2025. Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies ...